The FDA has granted full approval to selpercatinib for patients at least 2 years of age with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory, if appropriate. Additionally, repotrectinib received FDA accelerated approval for patients aged 12 or older with solid tumors harboring an NTRK gene fusion. Furthermore, nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin (BCG) has been approved for adult patients with BCG-unresponsive non-muscle invasive bladder cancer. IBI343 monotherapy received FDA fast track designation for advanced PDAC after 1 prior therapy, showing an ORR of 40% overall response rate in patients with CLDN18.2 expression. These approvals highlight the FDA's ongoing efforts to expand treatment options for various cancer types.
Innovative cancer treatments "are only as good as our ability to get them into the hands of our patients." Neha Verma @HopkinsMedicine tells the story of how a shortage of Pluvicto affected her patient's treatment for prostate cancer. Read the essay: https://t.co/7g8W1DmrV9 https://t.co/0FvYjhcAby
Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma. @LymphClinician @cityofhope @asco #ASCO24 #lymsm https://t.co/boFfW8p92v
Eric Vallieres, MD, FRCSC, advocates for tumor board review before deciding on treatment modalities and highlighted the importance of assessing the presence of any actionable driver mutations in NSCLC. @provswedish #lcsm #oncology https://t.co/JxbBssAT7V https://t.co/l2UmlLxPDb
Christian U. Blank, MD, PhD, discusses how a combination of two checkpoint inhibitors used as neoadjuvant therapy for Stage III #melanoma brought a highly statistically significant improvement over the #standardofcare. Listen here: https://t.co/swFcQwouhl. https://t.co/LilHjJiPF3
New treatment strategies in both the neoadjuvant and adjuvant settings are being implemented in NSCLC, which creates debate among oncologists over the benefits of neoadjuvant vs adjuvant IO approaches. @ProvSwedCancRes #lcsm #oncology #MedTwitter https://t.co/1nnQsh9GyB https://t.co/7vQBnEjwH2
A real-world analysis demonstrated the clinical benefit of tafasitamab as an early-line treatment for relapsed/refractory (R/R) diffuse large B-cell #lymphoma. https://t.co/CcRCVJXZdo #DLBCL https://t.co/8YYX2oS7u7
Lauren E. Nye, MD, highlights reasons to look beyond CDK4/6 inhibitors when determining treatments for patients with hormone receptor–positive advanced breast cancer and more. @DrLaurenNye @KUcancercenter #bcsm #oncology #MedTwitter https://t.co/ZHhdEeOUFD
Golidocitinib is the first JAK1-selective inhibitor approved for relapsed/refractory PTCL. #lymsm #oncology https://t.co/2teRDe6Poq https://t.co/wtkOvWXexC
In cohort 2B of the phase 2 KarMMa-2 trial, ide-cel induced durable responses for patients with functionally high-risk multiple myeloma who relapsed within 18 months of receiving first-line therapy. @CHU_de_Poitiers @EHA_Hematology #EHA2024 #mmsm https://t.co/PUGl2jmOb6 https://t.co/kLm21Wsk8m
Toripalimab-tpzi combined with etoposide and platinum significantly improves PFS and OS in ES-SCLC patients. #lcsm #oncology https://t.co/WqKRUIieTL
ICYMI: Blinatumomab is now FDA-approved for CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia in patients aged 1 month or older. @US_FDA #hematology #mpnsm https://t.co/l6steKsryJ https://t.co/E3Q10zFV8x
@LARVOL Onco Data Podcast | @DrBonillaOnc https://t.co/CEZmELSCtm
Frontline zanubrutinib plus rituximab induction followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin demonstrated antitumor activity in MCL. #mcl #lymsm https://t.co/aT1iZwDRa9 https://t.co/AXtJSKtDh8
In this episode of #OncLiveOnAir, Drs @DoctorDietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing. #oncology #meded https://t.co/nIxA0u20Cl #oncliveonair https://t.co/FPYKHwAjqJ
The #FDA approved nogapendekin alfa inbakicept-pmln with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive #bladdercancer. Keep reading: https://t.co/s5WE4ggGLN https://t.co/0Oyrz7bvf8
WU-CART-007 showed a 61.5% rate of grade 3 or higher TRAEs and an 88.5% incidence of CRS in patients with relapsed/refractory T-ALL/LBL. @EHA_Hematology #EHA2024 #leusm #lymsm #oncology https://t.co/YqEdoemPuz https://t.co/qzEikOjnWa
A significant proportion of patients with low- or intermediate-risk MF experienced disease progression over four years, with increasing rates over time in the MOST study. @LevineCancer @EHA_Hematology #EHA2024 https://t.co/23WvHbjf9z https://t.co/u4bjRuoIKN
Repotrectinib received FDA accelerated approval for patients aged 12 or older with solid tumors harboring an NTRK gene fusion. @US_FDA #oncology https://t.co/zIFmtaJ5Yz
Treatment with zanubrutinib and venetoclax produced a 100% ORR in treatment-naive patients with CLL/SLL harboring 17p deletions and/or TP53 mutations. @SanRaffaeleMI @EHA_Hematology #EHA2024 #lymsm #leusm https://t.co/knXzYsoYSy
Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower basal inflammation, lower tumor burden, and higher rates of early and sustained MRD negativity. @EHA_Hematology #EHA2024 #mmsm https://t.co/nX1Z99fJu0 https://t.co/hV4oitAgCO
Jean-Marc Classe, MD, PhD, discusses a new study that found that #lymphadenectomy should be omitted in advanced epithelial #ovariancancer patients with clinically negative lymph nodes. Listen to the #podcast here: https://t.co/3qfF44AJ0q. https://t.co/VUEvmOmQje
Marie Hu, MD, discusses considerations for the use of CAR T-cell therapy and bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma. @MarieHuMD @UMNHOT #lymsm https://t.co/PTFr6KSDsA
Luspatercept-aamt elicited superior erythroid response rates and duration of RBC-TI across all end points compared with epoetin alfa in patients with lower-risk MDS, according to findings from an analysis of the phase 3 COMMANDS trial. #mpnsm #oncology https://t.co/6gHr3DiFoE https://t.co/bBw6wH9PV1
Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma. @DrBattiwalla @SarahCannonDocs #oncology #mmsm https://t.co/IFUC22Iz0b
postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression @KalinskyKevin @emorymedicine @WinshipAtEmory @asco #ASCO24 #bcsm https://t.co/DLNBUzcoMN
Efficacy data for T-DXd derived from the phase 3 DESTINY-Breast06 trial could lead to further alteration of the treatment landscape for patients with hormone receptor–positive, HER2-low metastatic breast cancer. @DrVKGadi @uicancercenter #bcsm #oncology https://t.co/EPAtJfcakj https://t.co/pabH5AJS5H
Venetoclax plus obinutuzumab with or without ibrutinib significantly improved PFS vs standard chemoimmunotherapy and vs venetoclax plus rituximab in untreated patients with CLL. @TheLancetOncol #oncology #MedTwitter #leusm https://t.co/XLUHtFkXEp
IBI343 monotherapy received FDA fast track designation for advanced PDAC after 1 prior therapy, showing an ORR of 40% overall response rate in patients with CLDN18.2 expression. @US_FDA #pancsm https://t.co/CwBeN7FXL3 https://t.co/6B5S4gnbWc
Clinically meaningful activity was found across all subgroups of patients with R/R MCL in a posthoc subgroup analysis of the phase 1 TRANSCEND NHL 001 trial, which evaluated systemic therapy lines given prior to liso-cel. @EHA_Hematology #EHA2024 #lymsm https://t.co/iltCgrkyGy
Emavusertib demonstrated over 90% reduction in bone marrow blasts in responsive patients. @DanaFarber @DanaFarberNews #oncology https://t.co/cq5EsRzpca
As the role of T-DXd expands for pts w/ HER2+ breast cancer and novel ADCs enter the scene, increasing familiarity with these agents can optimize treatment outcomes and minimize toxicities. @dradityabardia @MassGeneralNews @MGHCancerCenter #bcsm https://t.co/PtLXkWIqcA https://t.co/tWxYRJZVxt
Capivasertib plus paclitaxel did not significantly improve overall survival in advanced TNBC in the CAPItello-290 trial. #oncology #bcsm https://t.co/lwr4dnJOIe
A new Phase II trial has shown that afamitresgene autoleucel is effective in treating advanced #synovialsarcoma and myxoid/round cell #liposarcoma, with a 37% overall response rate. Keep reading: https://t.co/Q2ENxC0dW5 https://t.co/5mup4u46E8
The FDA has granted full approval to selpercatinib for patients at least 2 years of age with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory, if appropriate. @US_FDA #oncology https://t.co/WwmXtNu6Dg
Joseph A. Greer, PhD, discusses how #telemedicine was shown to be as effective as face-to-face delivery by specialist clinicians for non-small cell #lungcancer, according to a study reported at #ASCO24. Listen to the podcast: https://t.co/EDpe7KLjcp. https://t.co/im5V3IDzCq
Switch Ramucirumab/Paclitaxel Maintenance Yields Favorable Outcomes in HER2– Gastric Cancer #oncology #MedTwitter #ESMOGI24 @myESMO https://t.co/5RJVTfes0Z
TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC #crcsm #oncology #ESMOGI24 @myESMO https://t.co/HrN2iKf9Sr